Rock Springs Capital Management’s Sage Therapeutics SAGE Stock Holding History

Rock Springs Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-92,500	Closed	-$13M	–	138
2019 Q3	$13M	Hold	92,500	–	–	0.52%	61
2019 Q2	$16.9M	Hold	92,500	–	–	0.61%	60
2019 Q1	$14.7M	Buy	92,500 +43,500	+89%	+$6.3M	0.57%	58
2018 Q4	$4.69M	Hold	49,000	–	–	0.22%	99
2018 Q3	$6.92M	Hold	49,000	–	–	0.25%	99
2018 Q2	$7.67M	Hold	49,000	–	–	0.3%	99
2018 Q1	$7.89M	Buy	49,000 +4,000	+9%	+$679K	0.34%	92
2017 Q4	$7.41M	Buy	45,000 +12,500	+38%	+$1.21M	0.34%	88
2017 Q3	$2.02M	Buy	+32,500	New	+$2.55M	0.09%	129

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Rock Springs Capital Management's SAGE Position: Q4 2019 in Review

Rock Springs Capital Management sold out of Sage Therapeutics (SAGE) in Q4 2019, closing a stake of 92,500 shares — an estimated $13M sold.

Rock Springs Capital Management first reported a position in SAGE in Q3 2017 and held it in 9 quarters. The position peaked at $16.9M in Q2 2019. 266 funds tracked by Wall St. Rank hold SAGE as of Q4 2019.

Rock Springs Capital Management reported no remaining Sage Therapeutics position as of Q4 2019 after selling out during the quarter.
Rock Springs Capital Management sold 92,500 Sage Therapeutics shares in Q4 2019, an estimated $13M.
Rock Springs Capital Management first reported a position in Sage Therapeutics in Q3 2017 and held it in 9 quarters.
Rock Springs Capital Management's Sage Therapeutics position peaked at $16.9M in Q2 2019.
266 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2019.

Based on Rock Springs Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.